The Resilience of the Down's Syndrome Genome
News Jan 22, 2018 | Original Story from University of Geneva
Credit: Carlos Palácio
Down’s syndrome – also known as trisomy 21 – is a genetic disorder caused by an additional third chromosome 21. Although this genetic abnormality is found in one out of 700 births, only 20% of foetuses with trisomy 21 reach full term. But how do they manage to survive the first trimester of pregnancy despite this heavy handicap? Researchers from the Universities of Geneva (UNIGE) and Lausanne (UNIL) have found that children born with Down’s syndrome have an excellent genome – better, in fact, than the average genome of people without the genetic abnormality. It is possible that this genome offsets the disabilities caused by the extra chromosome, helping the foetus to survive and the child to grow and develop. The study was published in the journal Genome Research.
Trisomy 21 is a serious genetic disorder, with four pregnancies out of five not reaching term naturally if the foetus is affected. However, 20% of conceptuses with Down’s syndrome are born live, grow up and can reach the age of 65. How is this possible? Researchers from UNIGE and UNIL hypothesised that individuals born with Down’s syndrome possess a high-quality genome that can compensate for the effects of the third chromosome 21.
Robust Testing of Down’s Genome
“The genome consists of all the genetic material that makes up an individual,” explains Stylianos Antonarakis, the honorary professor in UNIGE’s Faculty of Medicine who led the research. “It’s the genome that determines what becomes of a person, and makes him or her grow up and grow old, with or without disease. Some genomes are of better quality than others, and can also be less exposed to illnesses such as cancer.” Basing their work on the hypothesis of the quality of the genome, the geneticists tested the gene variation, regulation and expression of 380 individuals with Down’s syndrome and compared them to people without the genetic disorder.
The first test consisted of observing the presence of rare variants, i.e. potentially harmful genetic mutations, in people with Down’s. It is known that a chromosome can have different rare variants in its two copies. In a person with Down’s, however, the rare mutations that are identical for all three copies of chromosome 21 and limited in number, thereby reducing the total of potentially deleterious variants.
In a next step the geneticists studied the gene regulation on chromosome 21. Each gene has switches that regulate its expression either positively or negatively. Since people with Down’s have three chromosomes 21, most of these genes are overexpressed. “But we discovered that people with Down syndrome have more regulators that diminish the expression of the [chromosome] 21 genes, making it possible to compensate for the surplus induced by the third copy,” says Konstantin Popadin, a researcher at UNIL’s Center for Integrative Genomics.
Finally, the researchers focused on the variation gene expression for the chromosomes of the entire genome. Each gene expression on a scale from 0 to 100 forms part of a global spread curve, with the median – 50 – considered the ideal expression. “For a normal genome, the expressions oscillate between 30 and 70, while for a person with Down’s syndrome, the curve is narrower around the peak that is very close to 50 for genes on all the chromosomes,” continues Antonarakis. “In other words, this means that the genome of someone with Down’s leans towards the average – optimal functioning.” Indeed, the smaller the gene expression variations are, the better the genome.
A Superior Genome That Compensates for the Disability
The UNIGE and UNIL geneticists were thus able to test the three functions of genomes of people suffering from Down’s syndrome. “The research has shown that for a child with Down’s to survive pregnancy and then grow, his or her genome must be of a higher quality so that it can compensate for the disabilities caused by the extra copy of chromosome 21”, concludes Popadin. These conclusions may also apply to other serious genetic disorders where pregnancies reach full term.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.